Singapore, Feb. 9 -- South Korea-based startup Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has announced that its software solution, Neurophet AQUA AD Plus, a comprehensive neuroimaging analysis solution for clinical evaluation related to Alzheimer's disease, has received 510(k) clearance from the US Food and Drug Administration (FDA).

This clearance marks Neurophet's third FDA 510(k) clearance, following Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET image quantitative analysis software. The achievement further validates the safety and effectiveness of Neurophet's core product portfolio at a global regulatory standard.

Neur...